UB272
ProductAmoxicillin Sodium and Sulbactam Sodium for Injection
Strength0.5g: 0.25g; 1.0g: 0.5g; 2.0g: 1.0g
IndicationsUpper respiratory tract infection; Otitis media; Sinusitis; Tonsillitis; Pharyngitis; Lower respiratory tract infection; Pneumonia; Bronchitis; Chronic bronchitis; Bronchiectasis; Empyema; Lung abscess; Genitourinary tract infection; Pyelonephritis; Cystitis; Urethritis; Skin and soft tissue infection; Cellulitis; Wound infection; Furuncle; Impetigo; Pustular dermatitis; Sexually transmitted disease; Gonorrhoea; Pelvic infection; Puerperal infection; Oral abscess; Meningitis; Bacterial endocarditis; Peritonitis; Osteomyelitis; Typhoid fever; Paratyphoid fever; Endocarditis prophylaxis
TherapeuticsInfectious Diseases
GMPCN - NMPA
RegistrationChina
ModalitiesSmall Molecule
Exclusive Summary
- - No patent barriers worldwide; both actives are long off-patent, enabling rapid generic registration and distribution.
- - Targets high-burden infections with stable inpatient demand (≈150M UTIs/year, ≈30M adult CAP/year, ≈120M pediatric pneumonia episodes/year).
- - Aligned with beta-lactam/beta-lactamase inhibitor class for H. influenzae, MSSA, common TEM/SHV Enterobacterales and anaerobes; not on WHO EML, so access via national/hospital formularies.
- - Competition concentrated in Asia/CIS/LatAm with limited US/EU presence; full vial range (0.75/1.5/3.0 g total) supports hospital-tailored dosing.
- - Amoxicillin-based combo typically has lower COGS than ampicillin/sulbactam at the same 2:1 inhibitor ratio, allowing aggressive pricing vs class comparators.
我们能如何帮助您？
获取最新活动与法规动态洞察
直接发送到您的邮箱
在此获取行业洞察与 Unibest 动态
联系我们 →